Regenxbio
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $24,197 | $22,295 | $15,622 | $22,213 |
Gross Profit | 11,810 | 7,665 | 7,159 | 6,640 |
EBITDA | -54,816 | -48,489 | -57,177 | -57,343 |
EBIT | -58,777 | -52,540 | -61,356 | -61,678 |
Net Income | -59,597 | -52,989 | -63,330 | -62,889 |
Net Change In Cash | 24,197 | 22,295 | 15,622 | 22,213 |
Free Cash Flow | -40,875 | -45,971 | -56,012 | -41,886 |
Cash | 56,617 | 57,765 | 112,975 | 34,522 |
Basic Shares | 50,800 | 50,601 | 45,733 | 44,001 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $90,242 | $112,724 | $470,347 | $154,567 |
Gross Profit | 53,029 | 58,179 | 418,514 | 118,853 |
EBITDA | -239,464 | -244,242 | 169,544 | -96,832 |
EBIT | -256,784 | -257,151 | 159,980 | -105,239 |
Net Income | -263,494 | -280,321 | 127,840 | -111,250 |
Net Change In Cash | 90,242 | 112,724 | 470,347 | 154,567 |
Cost of Revenue | 7,483 | 268,912 | ||
Free Cash Flow | -228,367 | -238,212 | 134,700 | -80,930 |
Cash | 34,522 | 96,952 | 345,209 | 338,426 |
Basic Shares | 43,734 | 43,152 | 43,913 | 37,281 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.17 |
2024-06-30 | -$1.05 |
2024-03-31 | -$1.33 |
2023-12-31 | -$1.43 |
